Posted in | News

Advanced Ceramic Implant Manufacturer Files for IPO

Amedica Corporation today announced that it has filed a registration statement with the Securities and Exchange Commission (SEC) on Form S-1 for the proposed initial public offering of its common stock. All the offered shares will be sold by the Company. Amedica plans to list its common stock on the NASDAQ Global Market under the symbol AMCA.

Morgan Stanley & Co. Incorporated will act as sole bookrunning manager for the offering. Jefferies & Company, Inc. and CIBC World Markets Corp. will act as co-lead managers. When available, prospectuses may be obtained by contacting Morgan Stanley & Co. Incorporated, 180 Varick Street, 2nd Floor, New York, New York 10014, attention: Prospectus Department, 866-718-1649, or by e-mailing [email protected].

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to their registration or qualification under the securities laws of any such state or jurisdiction.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.